secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001628280-26-031269
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Q1 net loss narrows to $24.2M; ronde-cel PiNACLE on track for pivotal data mid-2027
--------------------------------------------------------------------------------

- Net loss $24.2M vs $52.2M a year ago; non-GAAP net loss $37.8M vs $46.3M.
- Cash $261M as of March 31, 2026, providing runway into Q3 2027.
- PiNACLE trial for ronde-cel in 3L+ LBCL: additional data H2 2026, pivotal data mid-2027, BLA submission 2027 expected.
- Phase 3 PiNACLE-H2H (ronde-cel vs standard CAR T) commenced dosing; LYL273 Phase 1 for mCRC at Dose Level 3.
- Closed second $50M tranche of private placement at $25.61/share; total $100M; Smital Shah appointed CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828026031269/0001628280-26-031269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828026031269/lyel-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer